Connect with us

Australia

Zelda Therapeutics and Ilera Therapeutics plan merger to “disrupt medicinal cannabis markets”

Zelda Therapeutics Ltd (ASX:ZLD) (FRA:G1G) (OTCMKTS:ZLDAF) is expected to increase its market capitalisation and reach on merging with fellow international medicinal cannabis company Ilera Therapeutics LLC to become Zelira Therapeutics.

Subject to approval from Zelda shareholders and all conditions of sale being met, Zelda is proposing to acquire 100% of Ilera through an all-scrip transaction.

Zelda reported that the merger would bring together a “leading pipeline of clinical candidates, revenue-generating medicines, and a combined strategy to disrupt global medicinal cannabis and pharmaceutical markets”.

Industry disruption is a goal in many industries, including medicinal cannabis, which is a fast-growing pharmaceutical market.

“Transformational opportunity”
Zelda's executive chairman Harry Karelis said, “This is a transformational opportunity for both companies.

“The merger will create one of the worlds leading medicinal cannabis companies with a rich pipeline of clinicall..

Zelda Therapeutics Ltd (ASX:ZLD) (FRA:G1G) (OTCMKTS:ZLDAF) is expected to increase its market capitalisation and reach on merging with fellow international medicinal cannabis company Ilera Therapeutics LLC to become Zelira Therapeutics.

Subject to approval from Zelda shareholders and all conditions of sale being met, Zelda is proposing to acquire 100% of Ilera through an all-scrip transaction.

Zelda reported that the merger would bring together a “leading pipeline of clinical candidates, revenue-generating medicines, and a combined strategy to disrupt global medicinal cannabis and pharmaceutical markets”.

Industry disruption is a goal in many industries, including medicinal cannabis, which is a fast-growing pharmaceutical market.

"Transformational opportunity"

Zelda's executive chairman Harry Karelis said, “This is a transformational opportunity for both companies.

“The merger will create one of the worlds leading medicinal cannabis companies with a rich pipeline of clinically validated products under development and unique access to the worlds largest and fastest-growing cannabis markets.”

Zelda is backed by key figures in the Australian biotechnology industry, including co-founders and directors Mara Gordon, Dr Stewart Washer and Karelis, and is jointly led by Karelis and managing director Dr Richard Hopkins.

The new Zelira will target international markets with its operations in Australia and the USA so it can access large, profitable and fast-growing medicinal cannabis market segments.

Zelira aims to bank receipts from HOPE brand Ilera cannabis formulations recently launched in Pennsylvania.

Revenue HOPEs

Ilera Therapeutics has rights to HOPE in other markets outside of the US state and has plans to market this and other products across the US and in global markets.

A Zelira dermatology subsidiary would also produce dermatology products created by board-certified cosmetic dermatologist Dr Karyn Grossman for the retail and cannabis regulated markets.

Zelda said its proposed merger would capture synergies and predicted it would help improve shareholder value for investors in both companies.

Karelis highlighted the potential for the merger to allow Zelda to speed up its plans to differentiate itself through “robust” clinical trials and be at the forefront of the medicinal cannabis sector worldwide.

He said, “The merger will enable the combined company to accelerate plans to disrupt the medicinal cannabis and pharmaceutical markets globally.”

An “excellent fit”

Ilera chairman Osagie Imasogie welcomed the merger, saying “Ilera Therapeutics and Zelda are an excellent and natural fit, given our respective clinical development straRead More – Source/a>

Continue Reading

Australia

Kangaroo Island Plantation Timbers invites bird lovers to assist with annual survey

Kangaroo Island Plantation Timbers Ltd (ASX:KPT) invites bird lovers to help out with the annual Birds in Plantations survey next month on Kangaroo Island in conjunction with Birdlife Australia.

Last year was the first time that bird surveys had been conducted in the companys plantations and there were 38 different bird species observed.

Birds were most abundant and diverse in the remnant vegetation on plantation properties.

KPT owns 25,000 hectares of land on Kangaroo Island, of which about 7,000 hectares is remnant vegetation.

Volunteers sought
In the 2018 Birds in Plantations survey, 22 volunteer surveyors completed more than 85 surveys across 37 different properties or control sites in KPT plantations.

This year the survey will be held on November 9 and 10, with volunteers able to complete surveys in the week before and after if they cannot commit to the weekend.

Building a picture of bird health
KPTs director of Community Engagement Shauna Black said the volunteers were cruc..

Kangaroo Island Plantation Timbers Ltd (ASX:KPT) invites bird lovers to help out with the annual Birds in Plantations survey next month on Kangaroo Island in conjunction with Birdlife Australia.

Last year was the first time that bird surveys had been conducted in the companys plantations and there were 38 different bird species observed.

Birds were most abundant and diverse in the remnant vegetation on plantation properties.

KPT owns 25,000 hectares of land on Kangaroo Island, of which about 7,000 hectares is remnant vegetation.

Volunteers sought

In the 2018 Birds in Plantations survey, 22 volunteer surveyors completed more than 85 surveys across 37 different properties or control sites in KPT plantations.

This year the survey will be held on November 9 and 10, with volunteers able to complete surveys in the week before and after if they cannot commit to the weekend.

Building a picture of bird health

KPTs director of Community Engagement Shauna Black said the volunteers were crucial to the success of the survey.

“You can do it in your own time and well provide fuel vouchers and safety equipment.

“Wed like to do it every year so we can build up a resource and a picture of bird health in our plantations, as part of our Forestry Stewardship Council certification.”

For more information Read More – Source

Continue Reading

Australia

Imugene welcomes receipt of US Department of Defense grant for City of Hope cancer researchers

Imugene Limited (ASX:IMU) has revealed that City of Hope researchers Yanghee Woo, MD and Yuman Fong, MD have received a $564,173 US Department of Defense Grant for the oncolytic virotherapy CF33 in gastric cancer.

Background
The CF33 oncolytic virus was developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California.

Imugenes proposal to license CF33 from City of Hope is awaiting satisfaction of customary conditions precedent and shareholder approval at the Extraordinary General Meeting (EGM) to be held on November 18, 2019.

Focus on gastric cancer
The grant focuses on the area of stomach (gastric) cancer (GC), a disease that disproportionately affects US military service members, veterans, and their beneficiaries who have increased exposure to hazardous environmental risk factors, such as H. pylori, Epstein-Barr viral infections, radiation, and tobacco smoking.

Peritoneal carcinomato..

Imugene Limited (ASX:IMU) has revealed that City of Hope researchers Yanghee Woo, MD and Yuman Fong, MD have received a $564,173 US Department of Defense Grant for the oncolytic virotherapy CF33 in gastric cancer.

Background

The CF33 oncolytic virus was developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California.

Imugenes proposal to license CF33 from City of Hope is awaiting satisfaction of customary conditions precedent and shareholder approval at the Extraordinary General Meeting (EGM) to be held on November 18, 2019.

Focus on gastric cancer

The grant focuses on the area of stomach (gastric) cancer (GC), a disease that disproportionately affects US military service members, veterans, and their beneficiaries who have increased exposure to hazardous environmental risk factors, such as H. pylori, Epstein-Barr viral infections, radiation, and tobacco smoking.

Peritoneal carcinomatosis (PC) is a fatal evolution of GC for which there is no effective treatment.

Across military families and the general population, over 60% of all patients with GC will develop peritoneal disease as the most common manifestation of recurrence or metastatic presentation.

The progression of primary GC to PC is facilitated by the unique peritoneal tumour microenvironment, where metastatic peritoneal seeding requires evasion of anti-tumour immunity and maintenance of a highly immunosuppressive microenvironment.

The researchers rationalize that a combined approach using Imugenes proposed license for novel oncolytic virus CF33 armed to express an anti-PD-L1 antibody as immune moRead More – Source

Continue Reading

Australia

Ironbark Zinc in trading halt ahead of capital raising news

Ironbark Zinc Ltd (ASX:IBG) has capital raising news pending and has been granted a trading halt by the ASX.

The halt will remain in place until the start of normal trading on Friday, October 25, 2019, or when an announcement is made to the market, whichever occurs earliest.

IBG's securities last traded at 1.7 cents, down from 2.1 cents in mid-September.

New managing director
In September the company appointed experienced commercial and corporate executive Michael Jardine to the role of managing director.

Jardines previous experience included director for Atrum Coal Ltd (ASX:ATU) and Pegasus Metals Ltd, which is now Scorpion Minerals Ltd (ASX:SCN).

He is currently a non-executive director of TNT Mines Ltd (ASX:TIN) as well as Read More – Source

Ironbark Zinc Ltd (ASX:IBG) has capital raising news pending and has been granted a trading halt by the ASX.

The halt will remain in place until the start of normal trading on Friday, October 25, 2019, or when an announcement is made to the market, whichever occurs earliest.

IBG's securities last traded at 1.7 cents, down from 2.1 cents in mid-September.

New managing director

In September the company appointed experienced commercial and corporate executive Michael Jardine to the role of managing director.

Jardines previous experience included director for Atrum Coal Ltd (ASX:ATU) and Pegasus Metals Ltd, which is now Scorpion Minerals Ltd (ASX:SCN).

He is currently a non-executive director of TNT Mines Ltd (ASX:TIN) as well as Read More – Source

Continue Reading

Trending